SOLO-1
Maintenance Olaparib in Newly Diagnosed BRCA-Mutated Advanced Ovarian Cancer
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 391 patients with newly diagnosed BRCA1/2-mutated advanced ovarian cancer in response to first-line platinum, maintenance olaparib for two years improved progression-free and overall survival compared with placebo.
N
391
Design
Double-blind RCT
Endpunkt
Progression-free survival
Relevanz
2
Ergebnis3-yr PFS HR 0.30 (median NR vs 13.8 months). 7-yr OS HR 0.55; 7-yr OS 67.0% vs 46.5%.
Moore K, et al. N Engl J Med. 2018;379(26):2495-2505. 10.1056/NEJMoa1810858
Diskussion & Kritik
Defined PARP-inhibitor maintenance as first-line standard in BRCA-mutated advanced ovarian cancer. PAOLA-1 extended this to the HRD-positive population on olaparib + bevacizumab.